Distinguished in Bone Tumor

Dr. Megan E. Daly

Radiation Oncology
Regents Of The Univ Of Ca
3850 G St, 
Merced, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Distinguished in Bone Tumor
Regents Of The Univ Of Ca
3850 G St, 
Merced, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Megan Daly is a Radiation Oncologist in Merced, California. Dr. Daly is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Gastrostomy, and Microvascular Decompression.

Her clinical research consists of co-authoring 119 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Bone Tumor.

Specialties
Radiation Oncology
Licenses
Radiology in CA
Hospital Affiliations
University Of California Davis Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

REGENTS OF THE UNIV OF CA
3850 G St, Merced, CA 95340

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Enrollment Status: Recruiting
Publish Date: May 25, 2025
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Paclitaxel, Veliparib
Study Phase: Phase 1/Phase 2
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Whole-Pelvic Radiotherapy With a Stereotactic Body Radiotherapy Boost and Long-Term Androgen Deprivation for Unfavorable-Intermediate and High Risk Localized Adenocarcinoma of the Prostate.
Whole-Pelvic Radiotherapy With a Stereotactic Body Radiotherapy Boost and Long-Term Androgen Deprivation for Unfavorable-Intermediate and High Risk Localized Adenocarcinoma of the Prostate.
Enrollment Status: Completed
Publish Date: October 18, 2022
Intervention Type: Radiation, Drug
Study Phase: Phase 1
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Enrollment Status: Completed
Publish Date: May 25, 2022
Intervention Type: Radiation
Study Phase: Phase 1
Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer
Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer
Enrollment Status: Completed
Publish Date: October 28, 2020
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: August 05, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 2
View 9 Less Clinical Trials

119 Total Publications

Clinical and economic impact of recurrence in unresected non-small cell lung cancer treated with primary stereotactic body radiotherapy: A real-world study using SEER-Medicare data.
Clinical and economic impact of recurrence in unresected non-small cell lung cancer treated with primary stereotactic body radiotherapy: A real-world study using SEER-Medicare data.
Journal: Journal of managed care & specialty pharmacy
Published: September 26, 2025
Similar Doctors
Distinguished in Bone Tumor
Dr. Ruben C. Fragoso
Radiation Oncology
Distinguished in Bone Tumor
Dr. Ruben C. Fragoso
Radiation Oncology

Regents Of The Univ Of Ca

3850 G St, 
Merced, CA 
 (0.1 miles away)
209-384-6528
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ruben Fragoso is a Radiation Oncologist in Merced, California. Dr. Fragoso is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Meningioma, Astrocytoma, Radiation Induced Meningioma, and Metastatic Brain Tumor.

Advanced in Bone Tumor
Dr. Darwin D. Yip
Radiation Oncology
Advanced in Bone Tumor
Dr. Darwin D. Yip
Radiation Oncology

Valley Cancer Medical Center Inc

1138 Norman Dr, 
Manteca, CA 
 (50.9 miles away)
209-823-1609
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Darwin Yip is a Radiation Oncologist in Manteca, California. Dr. Yip is rated as an Advanced provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Chordoma, Ewing Sarcoma, Bone Tumor, and Angiosarcoma of the Scalp.

Experienced in Bone Tumor
Dr. Nhat-long L. Pham
Radiation Oncology
Experienced in Bone Tumor
Dr. Nhat-long L. Pham
Radiation Oncology

Community Health Partners

45 E River Park Pl W, Suite 507, 
Fresno, CA 
 (50.0 miles away)
Languages Spoken:
English, Vietnamese
See accepted insurances
Offers Telehealth

Nhat-long Pham is a Radiation Oncologist in Fresno, California. Dr. Pham is rated as an Advanced provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Tongue Cancer, Throat Cancer, Laryngeal Cancer, Pleuropulmonary Blastoma, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Daly's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 18 Advanced Conditions
View All 41 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile